|
|
|
| 【主 题】 ： |
Quizartinib |
| 【联系人名】 ： |
Linna Green |
| 【电子邮件】 ： |
account@bocsci.com |
| 【联系电话】 ： |
15166698109 |
| 【发布日期】 ： |
2016-9-6 |
| 【详细说明】 ： |
Quizartinib is an orally available small molecule
with potential antineoplastic activity. Class III
receptor tyrosine kinase inhibitor AC220 selectively
inhibits class III receptor tyrosine kinases,
including FMS-related tyrosine kinase 3 (FLT3/STK1),
colony-stimulating factor 1 receptor (CSF1R/FMS),
stem cell factor receptor (SCFR/KIT), and platelet
derived growth factor receptors (PDGFRs), resulting
in inhibition of ligand-independent leukemic cell
proliferation and apoptosis. Mutations in FLT3,
resulting in constitutive activation, are the most
frequent genetic alterations in acute myeloid
leukemia (AML) and occur in approximately one-third
of AML cases.
In vitro: IC50 = 1.1 nM and 4.2 nM (for FLT3-ITD and
wt FLT3,
respectively).http://www.bocsci.com/quizartinib-cas-
950769-58-1-item-84-157290.html
|
|
|
|
|
English
